Harmonic (HLIT) Q1 2025 Earnings Call April 28, 2025 05:00 PM ET Company Participants David Hanover - Investor RelationsNimrod Ben-Natan - President & CEOWalter Jankovic - Chief Financial OfficerVictor Chiu - Equity Research Associate - Telecom & TechnologyAlyssa Shreves - Vice President - Equity Research Conference Call Participants Steven Frankel - Managing Director, Senior Research AnalystRyan Koontz - Managing Director - Research AnalystTim Savageaux - MD & Senior Research Analyst Operator Welcome to th ...

Financial Data and Key Metrics Changes - Revenue growth accelerated to 40% year over year in Q1 2025, up from 29% in Q4 2024, exceeding previous guidance of 28% to 31% [4][15] - Total revenue for Q1 2025 reached $143 million, with advertising revenue growing 63% and now representing two-thirds of total revenue [5][15] - Adjusted EBITDA was $32 million, with a margin of 23%, indicating increased profitability alongside revenue growth [6][15] Business Line Data and Key Metrics Changes - E-commerce was the fastest-growing vertical within advertising, achieving over 100% annualized growth, which offset typical seasonality [5][15] - Search revenue grew 8% year over year, indicating a slowdown compared to previous growth rates [5][32] - The user base remained stable at 293 million monthly active users (MAUs), with annualized ARPU increasing by 44% [7][15] Market Data and Key Metrics Changes - The U.S. market is experiencing greater uncertainty among advertisers, impacting growth potential [15][21] - The company has less exposure to U.S. e-commerce compared to competitors, suggesting significant growth opportunities ahead [22][63] Company Strategy and Development Direction - The company is focusing on high-value users and leveraging AI to optimize advertising and search revenue [6][10] - Opera is expanding its browser portfolio, including the introduction of AI-driven features, to enhance user experience and engagement [8][10] - The company aims to maintain aggressive growth in e-commerce while navigating macroeconomic challenges [21][63] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to grow despite a volatile macro environment, highlighting a strong track record of navigating challenges [13][21] - The company raised its full-year revenue guidance to DKK 567 million to DKK 582 million, reflecting confidence in continued growth [24][21] - Management noted that the advertising revenue is primarily performance-based, making it more resilient in uncertain economic conditions [22][67] Other Important Information - The company celebrated its 25th anniversary in 2025, emphasizing its long history of innovation and adaptation [13] - Opera has distributed $2.4 in dividends per share since January 2023, indicating a commitment to returning value to shareholders [21] Q&A Session Summary Question: Search growth during the quarter - Management acknowledged that the 8% growth in search revenue is a slowdown but attributed it to a shift towards intent-based advertising, which is driving overall advertising growth [32][34] Question: Decline in GX ARPU - Management noted that the decline in GX ARPU is partly seasonal and that the introduction of AI and high-intent advertising options is expected to benefit overall revenue [32][36] Question: Impact of currency on growth - Management indicated that the strong U.S. dollar has been a headwind, estimating that growth would have been 5 to 6 percentage points higher on a constant currency basis [38] Question: E-commerce growth and seasonality - Management confirmed that the rapid growth of e-commerce has offset typical seasonality, but acknowledged that seasonality will still be a factor as the business matures [41][44] Question: Concerns about MAU count - Management clarified that the focus is on high ARPU users rather than total MAU count, emphasizing revenue generation over user numbers [46][48] Question: U.S. antitrust actions and broader ecosystem - Management expressed that ongoing antitrust discussions could benefit Opera by increasing focus on competition and innovation in the browser market [49][52] Question: E-commerce opportunity and geographic exposure - Management highlighted that the e-commerce segment is growing rapidly and that the U.S. market still holds significant potential for future growth [56][58] Question: Gating factors for e-commerce growth - Management stated that attracting performance-focused advertisers is key to expanding e-commerce revenue, with a focus on larger retailers initially [61][64]

Financial Data and Key Metrics Changes - The company completed a public offering of common stock amounting to $56.5 million to support pipeline growth [5] - Cash and cash equivalents at the end of Q1 2021 were $64.5 million, expected to sustain operations into Q1 2023 [28] - Net loss for Q1 2021 was $8.8 million, an increase from a net loss of $6.5 million in Q1 2020 [28] - Research and development costs rose to $5.6 million in Q1 2021 from $3.8 million in Q1 2020, primarily due to increased headcount and infrastructure expenses [29] - General and administrative expenses increased to $3.1 million in Q1 2021 from $2.8 million in Q1 2020 [30] Business Line Data and Key Metrics Changes - The company initiated the safety lead-in portion of its Phase II trial for MT-401 in post-transplant acute myeloid leukemia (AML), treating the first patient in March 2021 [6][14] - The trial aims to enroll approximately six patients in the safety lead-in, with plans to open around 20 sites for the Phase II portion [15] - MT-401 has shown promising results in prior studies, with a 77% estimated two-year overall survival rate in patients post-infusion [18] Market Data and Key Metrics Changes - The company is focusing on the AML market, where current treatments have limited effectiveness, with only a 25% five-year survival rate for patients [6] - The MultiTAA therapy aims to address tumor heterogeneity and enhance immune response, potentially improving patient outcomes compared to existing therapies [12] Company Strategy and Development Direction - The primary focus for the year is completing the safety lead-in for the AML study and enrolling patients in the Phase II trial [10] - The company is optimizing its MT-401 cell therapy manufacturing process and plans to operationalize a new in-house facility [8] - The strategy includes exploring the application of manufacturing improvements across MultiTAA therapies to increase T cell availability [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of MT-401 in the AML patient population based on encouraging preliminary results [20] - The company is committed to addressing the unmet needs in cancer treatment and is exploring additional indications for future development [53] Other Important Information - The company has made significant technical and biological improvements in its manufacturing process, including a 50% reduction in manufacturing time and a 95% decrease in technical interventions [25][26] - The FDA has approved the changes in the manufacturing process, which are currently being implemented in the clinical study [27] Q&A Session Summary Question: Will there be disclosures after the safety lead-in trial? - Management indicated that safety data will be monitored and reported, with potential announcements regarding the main Phase II trial [32][33] Question: Could higher doses of MT-401 be used in the main Phase II trial? - Management confirmed that the new manufacturing process allows for the possibility of higher doses based on previous safety data [36][37] Question: How will manufacturing improvements impact cost and scalability? - Management noted that the simplified manufacturing process is expected to reduce costs and improve yield, making it suitable for future commercialization [43][44] Question: What are the next steps for collaboration with ABB on robotics? - Management expressed excitement about the collaboration, emphasizing the potential for improved consistency in the manufacturing process [49][50] Question: What are the key decision criteria for future indications? - Management highlighted the importance of unmet needs and data-driven decisions for exploring new indications beyond AML [53][54] Question: Update on Baylor's AML trial and higher dose testing? - Management stated that Baylor is nearing completion of the last dose level in their trial, with recent publications providing updates [58][60]

Financial Data and Key Metrics Changes - The company reported revenue from continuing operations of $43.8 million, a decrease from $48.5 million in the same quarter last fiscal year [19] - Net income from continuing operations increased significantly by over 2,000% year over year, reaching RMB3.2 million compared to RMB0.3 million in the same quarter last fiscal year [18][21] - Adjusted net income grew by 179.5% to RMB2.5 million compared to RMB1.3 million for the same quarter last fiscal year [21] Business Line Data and Key Metrics Changes - The schools business accounted for approximately 61% of total revenue, maintaining stable enrollment at 2,699 students year over year [7][9] - Revenue from the overseas study consulting business increased by 6.2% to RMB11.9 million [17][21] - Schools and other revenues were reported at $26.6 million and $5.3 million respectively [21] Market Data and Key Metrics Changes - The company achieved a 14.2% year-over-year improvement in revenue per enrollment at U.S. schools [8] - In the UK, students received offers from eight of the top 10 UK universities, including prestigious institutions like Cambridge and UCL [13][14] Company Strategy and Development Direction - The company is focused on executing a dual engine growth strategy, expanding its school business while enhancing global recruitment efforts [7][15] - There is a commitment to operational efficiency and maintaining high academic standards to drive sustainable long-term value [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver stronger long-term value to students, families, and shareholders, despite macroeconomic headwinds [15] - The company remains optimistic about capitalizing on the growing demand for premier international education [15] Other Important Information - SG&A expenses decreased by 30.7% year over year, improving the SG&A to revenue ratio by 1.2 percentage points [18][21] - The company reported a gross margin from continuing operations of 30%, slightly down from 30.8% in the same quarter last fiscal year [20] Q&A Session Summary - There were no questions during the Q&A session, indicating a lack of immediate inquiries from analysts or investors [23]

SuperCom (SPCB) Q4 2024 Earnings Call April 28, 2025 10:00 AM ET Company Participants Ordan Trabelsi - President and CEO Conference Call Participants Matthew Galinko - SVP & Senior Research AnalystGreg Mesniaeff - Research Analyst Operator Ladies and gentlemen, good morning, and welcome to Supercom's Fourth Quarter and Year End twenty twenty four Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen only mode. After today's presentation, there will be an oppo ...

Bright Scholar Education Holdings Limited (BEDU) Q2 2025 Earnings Call April 28, 2025 07:00 AM ET Company Participants Andrea Guo - Vice PresidentRobert Niu - CEOCindy Zhang - CFO Operator Hello, ladies and gentlemen. Thank you for standing by for Bright Scholar's Second Quarter of Fiscal Year twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After management's remarks, there will be a question and answer session. Today's conference call is being recorded. ...

Encompass Health (EHC) Q1 2025 Earnings Call April 26, 2025 01:15 AM ET Company Participants Mark Miller - Chief Investor Relations OfficerMark Tarr - CEO, President & DirectorDouglas Coltharp - Executive VP & CFONone - ExecutiveWhit Mayo - Senior Managing DirectorA.J. Rice - Managing DirectorJared Haase - Equity Research AssociateAndrew Mok - DirectorJohn Ransom - Managing Director, Director of Healthcare Research Conference Call Participants Pito Chickering - AnalystMatthew Gillmor - Director & Equity Res ...

SouthState (SSB) Q1 2025 Earnings Call April 25, 2025 10:27 PM ET Company Participants William Matthews - CFO & Executive VPJohn Corbett - CEO and DirectorMichael Rose - Managing DirectorSteven Young - Chief Strategy OfficerCatherine Mealor - Managing DirectorStephen Scouten - Managing DirectorRussell Gunther - Managing DirectorJared Shaw - Managing DirectorChristopher Marinac - Director of Research Conference Call Participants None - Analyst Operator Thank you for standing by. My name is Eric, and I will b ...

Principal Financial Group (PFG) Q1 2025 Earnings Call April 25, 2025 09:53 PM ET Company Participants Humphrey Lee - VP & Head of Investor RelationsDeanna Strable - President & CEOJoel Pitz - Senior Vice President and Interim Chief Financial OfficerRyan Krueger - Managing DirectorKamal Bhatia - President & CEO of Principal Asset Management, Principal Life & Principal FundsChristopher Littlefield - President of Retirement & Income SolutionsWilma Burdis - DirectorAmy Friedrich - President of Benefits & Protec ...

Saia (SAIA) Q1 2025 Earnings Call April 25, 2025 09:52 PM ET Company Participants Matthew Batteh - Executive VP, CFO & SecretaryFrederick Holzgrefe - President & CEOJonathan Chappell - Senior Managing DirectorJason Seidl - Managing DirectorDaniel Imbro - Managing DirectorRavi Shanker - Managing DirectorJ. Bruce Chan - DirectorKen Hoexter - Managing DirectorStephanie Moore - SVP - Equity Research Conference Call Participants Chris Wetherbee - Senior AnalystJordan Alliger - VP & Equity Research AnalystFadi Ch ...